Kidswell Bio Corporation
TSE:4584
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kidswell Bio Corporation
Selling, General & Administrative
Kidswell Bio Corporation
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
K
|
Kidswell Bio Corporation
TSE:4584
|
Selling, General & Administrative
-¥792.3m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-8%
|
|
|
SanBio Co Ltd
TSE:4592
|
Selling, General & Administrative
-¥1.1B
|
CAGR 3-Years
17%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-7%
|
|
|
GNI Group Ltd
TSE:2160
|
Selling, General & Administrative
-¥19B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-34%
|
|
|
PeptiDream Inc
TSE:4587
|
Selling, General & Administrative
-¥7.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
-31%
|
|
|
Takara Bio Inc
TSE:4974
|
Selling, General & Administrative
-¥18.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-7%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Selling, General & Administrative
-¥582.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
-1%
|
|
Kidswell Bio Corporation
Glance View
Kidswell Bio Corp. engages in the research and development of biopharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 39 full-time employees. The company went IPO on 2012-11-30. The biosimilar business is engaged in the research, development and provision of filgrastim biosimilar products and pegfilgrastim biosimilar products for cancer, darbepoetin alfa biosimilar products for renal diseases, and ranibizumab biosimilar products for eye diseases. The new biopharmaceutical business is engaged in the research and development of anti-RAMP2 antibodies for cancer and eye diseases, as well as new antibodies. The new biotechnology business is engaged in the development of regenerative medicine products that utilize intracardiac stem cells for pediatric congenital heart diseases, and regenerative medicine products that utilize dental pulp stem cells for cleft lip and palate and intestinal ganglion cell deficiency diseases, as well as the joint research business with universities.
See Also
What is Kidswell Bio Corporation's Selling, General & Administrative?
Selling, General & Administrative
-792.3m
JPY
Based on the financial report for Dec 31, 2025, Kidswell Bio Corporation's Selling, General & Administrative amounts to -792.3m JPY.
What is Kidswell Bio Corporation's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-8%
Over the last year, the Selling, General & Administrative growth was 4%. The average annual Selling, General & Administrative growth rates for Kidswell Bio Corporation have been 2% over the past three years , 1% over the past five years , and -8% over the past ten years .
